Clinical trials: HIV Reservoir
HIV
Evaluation of Innovative Combinatorial stratégies of Anti-latency and Anti-immune Activation Drugs Targeting HIV Reservoir
Several barriers prevent the remission of HIV infection: low level viremia, HIV latency in the genome of host infected immune cells and persistent immune activation.
- Trial name
- ERAVIR (NCT04741100)
- Testing
- Ex-vivo analysis
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV Infection
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Background: Antiretroviral therapy (ART) has been able to improve the lifespan of individuals infected with human immunodeficiency virus type 1 (HIV-1), but ART requires continuous treatment that has substantial consequences on…
- Trial name
- NCT01295515
- Testing
- Pegylated Interferon Alpha 2b (PEGINTRON)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
HIV/AIDS
Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir
To study the safety and effectiveness of the combination of Chidamide with Chimeric Antigen Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy on HIV patients based on cART.
- Trial name
- NCT03980691
- Testing
- Chidamide with CAR-T or TCR-T cell therapy
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV (Human Immunodeficiency Virus)
A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size
This study tests whether a medicine called ixazomib is safe for people living with HIV, and whether it can wake up HIV that is hiding in the body so the immune system and treatment can reach it.
- Trial name
- NCT07881809
- Testing
- Ixazomib 4 mg
- Where
- 20 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
The purpose of this study was to find out about the safety of sirolimus in individuals with HIV infection who were also being treated with ART.
- Trial name
- NCT02440789
- Testing
- Sirolimus
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections, HIV-1-infection
Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV
Combination antiretroviral therapy (cART) blocks intracellular human immunodeficiency virus (HIV) replication in CD4+ T-lymphocytes, but fails to eliminate latent HIV infected CD4+ T-lymphocytes.
- Conditions
- HIV Infections, HIV-1-infection, HIV-2 Infection
- Trial name
- EX VIVO (NCT05215704)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Erasmus Medical Center
Human Immunodeficiency Virus
Problems With Immune Recovery in the Gut Tissue
The aim of this study is to find out if the process of HIV replication in the lymph tissue and gut tissue of people taking HIV drugs causes long-term damage to the ability of the gut to protect you from other infections and…
- Trial name
- NCT01460433
- Testing
- Genital and rectal swabbing
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
HIV Infections
Integrase Inhibitor (MK-0518) Viral Decay
The eradication of HIV by antiretroviral therapy has thus far been elusive. It has been consistently demonstrated that a pool of latently infected, resting CD4+ T cells persists in the majority of HIV-infected individuals…
- Trial name
- NCT00520897
- Testing
- Raltegravir (MK0518), Leukopheresis, Sigmoid Biopsy
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Canadian Immunodeficiency Research Collaborative
HIV Infection
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
This study is a prospective, open-label, randomized, three-arm, dose-escalation exploratory pilot clinical trial involving HIV-1 infected participants treated with suppressive combination antiretroviral combination therapy…
- Trial name
- ACTIVATE (NCT02471430)
- Testing
- Panobinostat, Pegylated Interferon-alpha2a
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Hiv
HIV Study on MEasuring the Reservoir on Cellular Level to CUre Infection
The aim of this study is to gain new insights into HIV latency and reversal through extensive blood and tissues sampling (lymph node and colon biopsies) from 25 individuals under ART.
- Trial name
- HIV-Mercuri (NCT04305665)
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- University Hospital, Ghent
HIV Infections
Daclizumab to Treat HIV-Infected Patients
This study will examine the safety and effectiveness of daclizumab (also called Zenapax or anti-CD25) in reducing viral replication in patients with HIV infection.
- Trial name
- NCT00080431
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Therapeutic Vaccination in Treated HIV Disease
The central premise of our program is that durable control of HIV in the absence of antiretroviral therapy ("remission") will require the generation of de novo potent and sustained HIV-specific CD8+ cell responses that target…
- Trial name
- NCT03606213
- Testing
- PENNVAX-GP, INO-6145, INO-9012
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Steven Deeks
HIV Infections
IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients
To determine the efficacy of adding Isentress®, with or without Celsentri®, to effective conventional antiretroviral therapy (comprising at least 2 reverse transcriptase inhibitors and one boosted protease inhibitor), on residual…
- Trial name
- IntensVIH (NCT00935480)
- Testing
- Isentress®, Celsentri®
- Where
- 2 sites in France
- Volunteers
- 17 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
HIV Infections
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
The intensification with maraviroc in recently HIV-1-infected patients of a preferred gold-standard triple therapy composed of raltegravir plus tenofovir/emtricitabine could accelerate the decay of the HIV-1 reservoir in latently…
- Trial name
- NCT00808002
- Testing
- Raltegravir, Maraviroc, Tenofovir/Emtricitabine
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV-1, HIV Infections
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1
The presence of a pool of cells latently infected by HIV-1 in patients taking HAART and with a viral load below 50 copies/mL is the main limitation to eradication of the virus from the body.
- Trial name
- NCT00807443
- Testing
- Raltegravir
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
HIV Infections
CAR-T Cells for HIV Infection
This is a limited-center, open-label dose escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules in people with HIV infection. It will follow a 3+3 design.
- Trial name
- NCT04648046
- Testing
- Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Steven Deeks
HIV Infections
Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection
Pilot study to evaluate the impact of extremely early ART in the dynamics of viral reservoir, immune activation and inflammation in patients with HIV-1 infection of less than 20 days (Fiebig stages I-II) compared to patients with…
- Trial name
- VIRECURE (NCT02588820)
- Testing
- Antiretroviral Therapy (Experimental)
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- David Garcia Cinca
HIV-1 Infection
Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV
We propose to test our primary hypothesis that treatment with Peg-IFN-α-2b will result in a decrease in integrated HIV DNA in peripheral blood and tissue in chronically HIV-infected immune-reconstituted individuals (see section…
- Trial name
- NCT01935089
- Testing
- Pegylated Interferon alpha 2b
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- The Wistar Institute
HIV (Human Immunodeficiency Virus), HIV -1 Infection
Combining Latency Reversing Agents to Address the HIV Reservoir
The PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies ("shock and kill' strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which…
- Trial name
- PLUTO (NCT07384624)
- Testing
- Pyrimethamine (PYR), Lenalidomide, Topiramate (drug)
- Where
- 4 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
HIV
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
The main purpose of the study is to evaluate the safety of oral auranofin, a gold compound, in patients with HIV infection whose viral load has been suppressed by antiretroviral therapy for no less than 3 years and have a CD4+…
- Trial name
- Goldrake (NCT02176135)
- Testing
- Auranofin
- Where
- United States
- Sponsor
- Vaccine and Gene Therapy Institute, Florida